Four-Year Clinical Follow-Up of the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital Registry

American Journal of Cardiology

Volumn 101, Issue 8, 2008, Pages 1105-1111

  Daemen, Joost ^a   Kukreja, Neville ^a   van Twisk, Piet Hein ^a   Onuma, Yoshinobu ^a   de Jaegere, Peter P T ^a   van Domburg, Ron ^a   Serruys, Patrick W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BARE METAL STENT; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG ELUTING STENT; EVALUATION; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT SAFETY; PRIORITY JOURNAL; RAPAMYCIN ELUTING STENT; REGISTER; REVASCULARIZATION; STENT; THROMBOSIS;

AGE FACTORS; CASE-CONTROL STUDIES; CORONARY RESTENOSIS; CORONARY STENOSIS; CORONARY THROMBOSIS; DIABETES MELLITUS, TYPE 1; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; NETHERLANDS; REGISTRIES; SHOCK, CARDIOGENIC; SIROLIMUS; TIME FACTORS;

EID: 41449108482     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2007.11.074     Document Type: Article

References (27)

1. Kastrati A., Mehilli J., Pache J., Kaiser C., Valgimigli M., Kelbaek H., Menichelli M., Sabate M., Suttorp M.J., Baumgart D., et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356 (2007) 1030-1039
2. Daemen J., Wenaweser P., Tsuchida K., Abrecht L., Vaina S., Morger C., Kukreja N., Juni P., Sianos G., Hellige G., et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 369 (2007) 667-678
3. Spaulding C., Daemen J., Boersma E., Cutlip D.E., and Serruys P.W. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356 (2007) 989-997
4. Stone G.W., Moses J.W., Ellis S.G., Schofer J., Dawkins K.D., Morice M.-C., Colombo A., Schampaert E., Grube E., Kirtane A.J., et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 356 (2007) 998-1008
5. Stettler C., Wandel S., Allemann S., Kastrati A., Morice M.C., Schomig A., Pfisterer M.E., Stone G.W., Leon M.B., de Lezo J.S., et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 370 (2007) 937-948
6. Hordijk-Trion M., Lenzen M., Wijns W., de Jaegere P., Simoons M.L., Scholte op Reimer W.J.M., Bertrand M.E., Mercado N., Boersma E., and EHS-CR Investigators. Patients enrolled in coronary intervention trials are not representative of patients in clinical practice: results from the Euro Heart Survey on Coronary Revascularization. Eur Heart J 27 (2006) 671-678
7. Daemen J., Ong A.T., Stefanini G.G., Tsuchida K., Spindler H., Sianos G., de Jaegere P.P., van Domburg R.T., and Serruys P.W. Three-year clinical follow-up of the unrestricted use of sirolimus-eluting stents as part of the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry. Am J Cardiol 98 (2006) 895-901
8. Lemos P.A., Lee C.H., Degertekin M., Saia F., Tanabe K., Arampatzis C.A., Hoye A., van Duuren M., Sianos G., Smits P.C., et al. Early outcome after sirolimus-eluting stent implantation in patients with acute coronary syndromes: insights from the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry. J Am Coll Cardiol 41 (2003) 2093-2099
9. Lemos P.A., Serruys P.W., van Domburg R.T., Saia F., Arampatzis C.A., Hoye A., Degertekin M., Tanabe K., Daemen J., Liu T.K., et al. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world": the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation 109 (2004) 190-195
10. Ong A.T., Serruys P.W., Aoki J., Hoye A., van Mieghem C.A., Rodriguez-Granillo G.A., Valgimigli M., Sonnenschein K., Regar E., van der Ent M., et al. The unrestricted use of paclitaxel- versus sirolimus-eluting stents for coronary artery disease in an unselected population: one-year results of the Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registry. J Am Coll Cardiol 45 (2005) 1135-1141
11. Smith J., Sidney C., Feldman T.E., Hirshfeld J., John W., Jacobs A.K., Kern M.J., King III S.B., Morrison D.A., O'Neill W.W., et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention-summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol 47 (2006) 216-235
12. Smith S.C., Dove J.T., Jacobs A.K., Kennedy J.W., Kereiakes D., Kern M.J., Kuntz R.E., Popma J.J., Schaff H.V., Williams D.O., et al. ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines)-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1993 Guidelines for Percutaneous Transluminal Coronary Angioplasty) endorsed by the Society for Cardiac Angiography and Interventions. J Am Coll Cardiol 37 (2001) 2215-2238
13. Ong A.T., Hoye A., Aoki J., van Mieghem C.A., Rodriguez Granillo G.A., Sonnenschein K., Regar E., McFadden E.P., Sianos G., van der Giessen W.J., et al. Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol 45 (2005) 947-953
14. Cutlip D.E., Windecker S., Mehran R., Boam A., Cohen D.J., van Es G.-A., Gabriel Steg P., Morel M.-A., Mauri L., Vranckx P., and Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115 (2007) 2344-2351
15. Ong A.T., van Domburg R.T., Aoki J., Sonnenschein K., Lemos P.A., and Serruys P.W. Sirolimus-eluting stents remain superior to bare-metal stents at two years: medium-term results from the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry. J Am Coll Cardiol 47 (2006) 1356-1360
16. Mauri L., Hsieh W.-H., Massaro J.M., Ho K.K.L., D'Agostino R., and Cutlip D.E. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 356 (2007) 1020-1029
17. Daemen J., Wenaweser P., Jüni P., van Domburg R., Schmidlin K., Zwahlen M., Windecker S., and Serruys P.W. Late coronary stent thrombosis of DES in routine clinical practice ESC (2007) Vienna
18. Alfonso F., Suarez A., Perez-Vizcayno M.J., Moreno R., Escaned J., Banuelos C., Jimenez P., Bernardo E., Angiolillo D.J., Hernandez R., and Macaya C. Intravascular ultrasound findings during episodes of drug-eluting stent thrombosis. J Am Coll Cardiol 50 (2007) 2095-2097
19. Farb A., Burke A.P., Kolodgie F.D., and Virmani R. Pathological mechanisms of fatal late coronary stent thrombosis in humans. Circulation 108 (2003) 1701-1706
20. Joner M., Finn A.V., Farb A., Mont E.K., Kolodgie F.D., Ladich E., Kutys R., Skorija K., Gold H.K., and Virmani R. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 48 (2006) 193-202
21. Park S.-J. Asan Medical Center DES Registry: outcomes of drug-eluting compared to bare metal stents from two academic hospitals in Korea (1- and 3-year follow-up) TCT (2007) Washington, DC
22. Harjai K. GHOST: outcomes of drug-eluting compared to bare metal stents from the Guthrie Health System (2- to 3-year follow-up) TCT (2007) Washington, DC
23. James S.K. SCAAR update: outcomes of drug-eluting compared to bare metal stents in the country of Sweden TCT (2007) Washington, DC
24. Jensen L.O. Western Denmark: outcomes of Drug eluting stents compared to bare metal stents in western Denmark (2-year follow-up) TCT (2007) Washington, DC
25. Brodie B.R. STENT registry: outcomes of drug-eluting compared to bare metal stents from multiple use hospitals (2-year follow-up) TCT (2007) Washington, DC
26. Lagerqvist B., James S.K., Stenestrand U., Lindback J., Nilsson T., Wallentin L., and SCAAR Study Group. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 356 (2007) 1009-1019
27. Serruys P.W., and Daemen J. The SCAAR registry or the Swedish yo-yo. EuroIntervention 3 (2007) 297-300